DBDx-based drug combinations show highly potent therapeutic efficacy against human pancreatic cancer xenografts in athymic mice

References

• Ilic M, Ilic I. 2016. Epidemiology of pancreatic cancer. World J Gastroenterol. 22:9694–9705. doi:10.3748/wjg.v22.i44.9694.
   PubMed Web of Science ®Google Scholar
• Mohammed A, Janakiram NB, Madka V, Li M, Asch AS, Rao CV. 2018. Current challenges and opportunities for chemoprevention of pancreatic cancer. Curr Med Chem. 25:2535–2544. doi:10.2174/0929867324666170209104453.
   PubMed Web of Science ®Google Scholar
• Tanase CP, Neagu AI, Necula LG, Mambet C, Enciu AM, Calenic B, Cruceru ML, Albulescu R. 2014. Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics. World J Gastroenterol. 20:10790–10801. doi:10.3748/wjg.v20.i31.10790.
   PubMed Web of Science ®Google Scholar
• Teague A, Lim KH, Wang-Gillam A. 2015. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther Adv Med Oncol. 7:68–84. doi:10.1177/1758834014564775.
   PubMed Web of Science ®Google Scholar
• Bittoni A, Andrikou K, Lanese A, Santoni M, Pellei C, Faloppi L, Del Prete M, Giampieri R, Cascinu S. 2015. Treatment of pancreatic cancer. Actuality and perspective. Recenti Prog Med. 106:208–216. doi:10.1701/1868.20404.
   PubMedGoogle Scholar
• Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al. 2011. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. doi:10.1056/NEJMoa1011923.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. 2013. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. doi:10.1056/NEJMoa1304369.
   PubMed Web of Science ®Google Scholar
• Liu XJ, Zheng YB, Li Y, Wu SY, Zhen YS. 2014. A multifunctional drug combination shows highly potent therapeutic efficacy against human cancer xenografts in athymic mice. PLoS One. 9:e115790. doi:10.1371/journal.pone.0115790.
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. 1997. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 15:2403–2413. doi:10.1200/JCO.1997.15.6.2403.
   PubMed Web of Science ®Google Scholar
• Sidaway P. 2017. Pancreatic cancer: addition of capecitabine prolongs overall survival. Nat Rev Clin Oncol. 14:198. doi:10.1038/nrclinonc.2017.21.
   Google Scholar
• Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, et al. 2009. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 27:5513–5518. doi:10.1200/JCO.2009.24.2446.
   PubMed Web of Science ®Google Scholar
• Chung KH, Ryu JK, Son JH, Lee JW, Jang DK, Lee SH, Kim YT. 2017. Efficacy of capecitabine plus oxaliplatin combination chemotherapy for advanced pancreatic cancer after failure of first-Line gemcitabine-based therapy. Gut Liver. 11:298–305. doi:10.5009/gnl16307.
   PubMed Web of Science ®Google Scholar
• Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, Cox JV, Schulz JJ. 2002. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol. 20:160–164. doi:10.1200/JCO.2002.20.1.160.
   PubMed Web of Science ®Google Scholar
• van den Borne P, Quax PH, Hoefer IE, Pasterkamp G. 2014. The multifaceted functions of CXCL10 in cardiovascular disease. Biomed Res Int. 2014:893106. doi:10.1155/2014/893106.
   PubMed Web of Science ®Google Scholar
• Lee EY, Lee ZH, Song YW. 2009. CXCL10 and autoimmune diseases. Autoimmun Rev. 8:379–383. doi:10.1016/j.autrev.2008.12.002.
   PubMed Web of Science ®Google Scholar
• Komai T, Okamura T, Yamamoto K, Fujio K. 2016. The effects of TGF-βs on immune responses. Nihon Rinsho Meneki Gakkai Kaishi. 39:51–58. doi:10.2177/jsci.39.51.
   PubMedGoogle Scholar
• Hao S, Han X, Wang D, Yang Y, Li Q, Li X, Qiu CH. 2016. Critical role of CCL22/CCR4 axis in the maintenance of immune homeostasis during apoptotic cell clearance by splenic CD8α(+) CD103(+) dendritic cells. Immunology. 148:174–186. doi:10.1111/imm.12596.
   PubMed Web of Science ®Google Scholar
• Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. 2002. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern cooperative oncology group trial E2297. J Clin Oncol. 20:3270–3275. doi:10.1200/JCO.2002.11.149.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, et al. 2006. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 24:3946–3952. doi:10.1200/JCO.2005.05.1490.
   PubMed Web of Science ®Google Scholar
• Zhang YD, Yang Q, Jiang ZM, Ma W, Zhou SW, Xie DR. Overall survival of patients with advanced pancreatic cancer improved with an increase in second-line chemotherapy after gemcitabine-based therapy. JOP. 2011;12:131–137.
   PubMedGoogle Scholar
• Oberstein PE, Olive KP. 2013. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 6:321–337. doi:10.1177/1756283X13478680.
   PubMed Web of Science ®Google Scholar
• Hoshi N, Kofunato Y, Yashima R, Shimura T, Takenoshita S. Treating side effects of FOLFIRINOX–A study of the effect of Hange-Shashin-To on preventing diarrhea. Gan To Kagaku Ryoho. 2015;42:2364–2366.
   PubMedGoogle Scholar
• Kimbara S, Kondo S. 2016. Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World J Gastroenterol. 22:7440–7452. doi:10.3748/wjg.v22.i33.7440.
   PubMed Web of Science ®Google Scholar
• Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K. 2006. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res. 12:3003–3009. doi:10.1016/j.urolonc.2006.12.007.
   PubMed Web of Science ®Google Scholar
• Fan Z, Sehm T, Rauh M, Buchfelder M, Eyupoglu IY, Savaskan NE. 2014. Dexamethasone alleviates tumor associated brain damage and angiogenesis. PLoS One. 9:e93264. doi:10.1371/journal.pone.0093264.
   PubMed Web of Science ®Google Scholar
• Aozuka Y, Koizumi K, Saitoh Y, Ueda Y, Sakurai H, Saiki I. 2004. Anti-tumor angiogenesis effect of aminopeptidase inhibitor bestatin against B16–BL6 melanoma cells orthotopically implanted into syngeneic mice. Cancer Lett. 216:35–42. doi:10.1016/j.canlet.2004.06.050.
   PubMed Web of Science ®Google Scholar
• Spano D, Marshall JC, Marino N, De Martino D, Romano A, Scoppettuolo MN, Bello AM, Di Dato V, Navas L, De Vita G, et al. 2013. Dipyridamole prevents triple-negative breast-cancer progression. Clin Exp Metastasis. 30:47–68. doi:10.1007/s10585-012-9506-0.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. 2016. Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. doi:10.3322/caac.21338.
   PubMed Web of Science ®Google Scholar
• Zheng YB, Gong JH, Liu XJ, Li Y, Zhen YS. 2017. A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis. Mol Carcinog. 56:1395–1404. doi:10.1002/mc.22600.
   PubMed Web of Science ®Google Scholar